Trending...
- King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
- South Tacoma Glass Recycling Drop-Off Location Closing
- ChargeOn Announces Conversational Payment Management Solution
SEATTLE ~ AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has been awarded a special mention for Research and Innovation led by Executives Under the Age of 40 by Confindustria. Confindustria is the main association representing manufacturing and service companies in Italy, with a voluntary membership of more than 150,000 companies of all sizes, employing a total of 5,383,286 people.
The AGC Biologics Milan site has a strong team of life science professionals, with 72% of the workforce being under the age of 40. The site's leadership promotes a dynamic and diverse environment to support these team members in their mission to help pharmaceutical companies bring lifesaving treatments to market. 80% at the site hold college degrees, and among those, 16% have achieved a PhD. 61% of leadership positions are held by women.
Francesco De Santis, Vice President of Confindustria for Research and Development noted that "the award is a recognition of companies that have stood out for the quality of innovation" and that "a national commitment is necessary to go with this process and make the national research, development, and innovation system increasingly integrated".
More on Washingtoner
Luca Alberici from AGC Biologics Milan said "this award showcases the work and potential of our business and the young professionals here in Milan that help make our site so successful". He added that "our entire team is driven by innovation in the workplace and delivering the highest level of quality in our work, to ensure patients get the treatments they need".
AGC Biologics acquired its Milan site (formerly MolMed S.p.A.) to add a cell and gene CDMO business to its offerings in July 2020; it has since become the global hub for their cell and gene therapy services. The team at this site has brought multiple products from pre-clinical through commercial phases as well as developed custom plug-and-play systems for vector manufacturing such as AGC's BravoAAV™ and ProntoLVV™ platforms.
The award from Confindustria recognizes AGC Biologics' commitment to research & development as well as their dedication to providing innovative solutions for their clients while also promoting diversity within their workforce.
The AGC Biologics Milan site has a strong team of life science professionals, with 72% of the workforce being under the age of 40. The site's leadership promotes a dynamic and diverse environment to support these team members in their mission to help pharmaceutical companies bring lifesaving treatments to market. 80% at the site hold college degrees, and among those, 16% have achieved a PhD. 61% of leadership positions are held by women.
Francesco De Santis, Vice President of Confindustria for Research and Development noted that "the award is a recognition of companies that have stood out for the quality of innovation" and that "a national commitment is necessary to go with this process and make the national research, development, and innovation system increasingly integrated".
More on Washingtoner
- Tacoma Dome Unveils Salish Mural
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- Tacoma: Northbound I-705 Stadium Way Off-Ramp to Close at Noon Today for Emergency Repairs
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- PeopleNTech LLC to Participate in CWS Summit North America 2026
Luca Alberici from AGC Biologics Milan said "this award showcases the work and potential of our business and the young professionals here in Milan that help make our site so successful". He added that "our entire team is driven by innovation in the workplace and delivering the highest level of quality in our work, to ensure patients get the treatments they need".
AGC Biologics acquired its Milan site (formerly MolMed S.p.A.) to add a cell and gene CDMO business to its offerings in July 2020; it has since become the global hub for their cell and gene therapy services. The team at this site has brought multiple products from pre-clinical through commercial phases as well as developed custom plug-and-play systems for vector manufacturing such as AGC's BravoAAV™ and ProntoLVV™ platforms.
The award from Confindustria recognizes AGC Biologics' commitment to research & development as well as their dedication to providing innovative solutions for their clients while also promoting diversity within their workforce.
0 Comments
Latest on Washingtoner
- Tacoma: Applicants Sought for the Board of Ethics
- Tacoma: Applicants Sought for the Landmarks Preservation Commission
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- Tacoma: Arrest Made in 2021 Homicide
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Continuous You Foundation Announces Partnership with Haawke Neural Technology
- Metamora Events Brings New Interactive Event Experiences to Portland and Vancouver
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- Lake Norman Philharmonic - Free Community Concert
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Spokane Police Officers Arrest "Grave Robber"
- Spokane: "Keep Kids Moving" – A Fund to Help Replace Recreation and Sports Gear
- Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!